I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology Macula Society 2025
Roche and Genentech at

Macula Society 2025

February 12 - February 15
Florida, USA
maculasociety.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Feb 21 / Roche and Genentech
Impact of Early Intraretinal Fluid Reduction on One-Year Outcomes in Diabetic Macular Edema
This presentation describes an analysis investigating the relationship between the reduction in intraretinal fluid volume after 3 months of treatment and 2-year anatomic and visual outcomes in patients with diabetic macular edema. This post hoc analysis is based on treatment agnostic data from the phase 3 YOSEMITE and RHINE trials.
Ophthalmology Diabetic Macular Edema MACULA-SOCIETY-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 18 / Roche and Genentech
Retinal Fluid and Thickness Fluctuations in Pagoda Trial of PDS in Patients With DME
This presentation describes results from a post hoc analysis investigating retinal fluid and thickness fluctuations and the impact of these features on vision outcomes in patients with DME in the phase 3 Pagoda trial. In patients with DME, continuous delivery with PDS controlled retinal fluctuations and maintained vision over 48 weeks, comparable to IVT.
Ophthalmology Diabetic Macular Edema MACULA-SOCIETY-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 16 / Roche and Genentech
Implementation of Optimized Surgical Steps for the PDS and the Incidence of Endophthalmitis and Associated Patient Outcomes
This presentation decribes results from a retrospective analysis which examined the impact of surgical improvements on endophthalmitis incidence and patient outcomes over time in patients receiving the Port Delivery Platform with ranibizumab (PDS) in the PDS clinical development program from 2016 to 2024. A trend for improvement in endophthalmitis incidence and patient outcomes was observed after June 2020. Key updates, increased awareness, better monitoring and management in the PDS clinical trial program have all contributed to this positive trend.
Ophthalmology Neovascular Age Related Macular Degeneration Diabetic Retinopathy Diabetic Macular Edema MACULA-SOCIETY-2025
09:04 PM
Duration 5mins United States
Treatment Response and Safety of Faricimab▼ in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US
Scott A, Amador M, Brown J, Cunningham M, Coney J, Emanuelli A, Huddleston S, Milunovich S, Yang M, Lu XY, Gonzalez L
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:09 PM
Duration 5mins United States
Four-Year Outcomes of Faricimab▼ in DME: Safety and Efficacy Results From The RHONE-X Long-Term Extension Trial
Khanani A, Abreu F, Gibson K, Kotak A, Lai TYY, Pearce I, Schlottmann P, Sim D, Tang Y, Kotecha A
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:14 PM
Duration 5mins United States
Greater reduction in hard exudates with faricimab▼ vs aflibercept in patients with DME: biomarker results from the phase 3 YOSEMITE/RHINE trials
Elman M, Pollreisz A, Dinah C, Goldberg R, Ip M, Rahimy E, Vujosevic S, Amador M, Gibson K, Maunz A, O'Leary O, Uschner D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:50 PM
Duration 5mins United States
Impact of Early Intraretinal Fluid Reduction on One-Year Outcomes in Diabetic Macular Edema
Chan C, Sadda S, Lim J, Wang Y, Hibar D, Maunz A, Lu H, Albrecht T, Amador M, Gibson K, Litts K
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:25 PM
Duration 5mins United States
Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With nAMD or DME From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study
Schmitz-Valckenberg S, Bailey C, Chaikitmongkol V, Chaudhary V, Chi G, Downey A, Finger R, Gallego-Pinazo R, Koh A, Ishida S, Lövestam-Adrian M, Parravano M, Pinto JL, Sheth V, Shi B, Souied E, Uschner D, Guymer R
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:30 PM
Duration 5mins United States
Treatment Patterns, Visual Outcomes, and Safety in Eyes With nAMD and DME Treated With Faricimab▼ in the UK: 1-Year Results From the FARWIDE Study
Sivaprasad S, Pearce I, Talks J, Salvo G, Patel P, Silva S, Gale R, McKibbin M, Varma D, Peto T, Reynolds R, Bailey C, Downey L, Kiire C, Chi G, Dodds M, James N, Downey A, Dayal P
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:35 PM
Duration 5mins United States
Real-World Clinical Outcomes Update in Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Treated With Faricimab▼ in the US: The FARETINA Study
Borkar D, Zwick E, Bonine N, Leng T, Ko S, Shaia J, Ali F, Singh R
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:50 PM
Duration 10mins United States
Clinical Impact of Continuous Drug Delivery With the PDS in Patients With nAMD
Arevalo JF, Chakravarthy U, Rachitskaya A, Holekamp N, Blotner S, Garcia Armendariz B, Heinrich D
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:20 PM
Duration 10mins United States
Comparative Efficacy of Faricimab▼ for the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis
Wells J, Lupidi M, Keane P, Holekamp N, Leng T, Siedlecki J, Mar F, Gibson K, Margaron P, Paulo T, Buehrer C, Tabano D
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:40 PM
Duration 10mins United States
Baseline and Early Treatment Response Variables Associated With Faricimab▼ Durability in Treatment-nave nAMD: TENAYA/LUCERNE Post Hoc Analyses
Tan C, Gallego-Pinazo R, Koh A, Pitcher J, Dagincourt N, Hill L, Patel S, Margaron P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:50 PM
Duration 10mins United States
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
Cheung G, Chen SJ, Iida T, Koh A, Lee WK, Ruamviboonsuk P, Sun X, Yanagi Y, Bai R, Margaron P, Nguyen Duc A, Lai TYY
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:20 PM
Duration 5mins United States
Interleukin-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: DOVETAIL, MEERKAT, and SANDCAT Trials
Holecamp N, Lin P, Steeples L, Elze M, Macgregor L, Stoilov I, Silverman D, Mesquida M, Haskova Z
Ophthalmology | Uveitis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:35 PM
Duration 5mins United States
Implementation of Optimized Surgical Steps for the PDS and the Incidence of Endophthalmitis and Associated Patient Outcomes
Chaudhry N, Campochiaro P, Chang M, Pieramici P, Regillo C, Bobbala A, Gune S, Jaycock P, Kardatzke D, Prager A, Singh N
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Retinopathy - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:20 PM
Duration 10mins United States
Retinal Fluid and Thickness Fluctuations in Pagoda Trial of PDS in Patients With DME
Tan G, D Marcus, Awh C, Eter N, Hatz K, Menezes A, Eghoej M, Gordon A, Blotner S, Heinrich D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.